Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708 PMID: 35020204
   PubMed Web of Science ®Google Scholar
• Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541. doi: 10.3322/caac.21754 PMID: 36190501
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691–722. doi: 10.6004/jnccn.2022.0030 PMID: 35714673.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617–628. doi: 10.1056/NEJMoa1814017 PMID: 30516102.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. doi: 10.1016/S1470-2045(11)70336-9 PMID: 22153890
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–84. doi: 10.1093/annonc/mdt182 Epub 2013 May 22. PMID: 23704196.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810–821. doi: 10.1056/NEJMoa1910549 PMID: 32101663.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121. doi: 10.1056/NEJMoa1804710 PMID: 29860917; PMCID: PMC6172658.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–2347. doi: 10.1056/NEJMoa2108873 PMID: 34914339; PMCID: PMC9096864.
   PubMed Web of Science ®Google Scholar
• Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–785. doi: 10.1200/JCO.2007.15.0235 PMID: 18258986
   PubMed Web of Science ®Google Scholar
• Marron TU, Galsky MD, Taouli B, et al. Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. Nat Med. 2022;28(4):626–629. doi: 10.1038/s41591-022-01681-x PMID: 35347282.
   PubMed Web of Science ®Google Scholar
• Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159. doi: 10.1056/NEJMoa1612645 PMID: 28564564.
   PubMed Web of Science ®Google Scholar
• Lluch A, Barrios CH, Torrecillas L, et al. GEICAM Spanish breast cancer group; CIBOMA (Iberoamerican coalition for research in breast oncology); LACOG (latin American cooperative oncology group). Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020;38(3):203–213. doi: 10.1200/JCO.19.00904 PMID: 31804894; PMCID: PMC6968797.
   PubMed Web of Science ®Google Scholar
• Francis JWM, Saundh M, Parks RM, et al. Molecular biomarker expression in window of opportunity studies for oestrogen receptor positive breast cancer-A systematic review of the literature. Cancers (Basel). 2022;14(20):5027. doi: 10.3390/cancers14205027 PMID: 36291809; PMCID: PMC9599781.
   PubMed Web of Science ®Google Scholar
• [cited 2023 Dec 9]. Available from: www.pubmed.ncbi.nlm.nih.gov
   Google Scholar
• Collins PM, Brennan MJ, Elliott JA, et al. Neoadjuvant chemotherapy for luminal a breast cancer: factors predictive of histopathologic response and oncologic outcome. Am J Surg. 2021;222(2):368–376. doi: 10.1016/j.amjsurg.2020.11.053 PMID: 33334569
   PubMed Web of Science ®Google Scholar
• Chic N, Schettini F, Brasó-Maristany F, et al. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. EBioMedicine. 2021;69:103451. doi: 10.1016/j.ebiom.2021.103451 PMID: 34161883; PMCID: PMC8233691.
   PubMed Web of Science ®Google Scholar
• Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–2848. doi: 10.1158/1078-0432.CCR-19-3492 PMID: 32046998; PMCID: PMC7299787
   PubMed Web of Science ®Google Scholar
• Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(9):2411–2418. doi: 10.1245/s10434-010-1008-1 PMID: 20373039; PMCID: PMC2924493.
   PubMed Web of Science ®Google Scholar
• Zeidman M, Alberty-Oller JJ, Ru M, et al. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study. Breast Cancer Res Treat. 2020;184(1):203–212. doi: 10.1007/s10549-020-05809-w PMID: 32740807.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–756. doi: 10.1016/S1470-2045(14)70160-3 PMID: 24794243
   PubMed Web of Science ®Google Scholar
• Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTness): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497–509. doi: 10.1016/S1470-2045(18)30111-6 PMID: 29501363
   PubMed Web of Science ®Google Scholar
• Gwark S, Noh WC, Ahn SH, et al. Axillary lymph node dissection rates and prognosis from phase III neoadjuvant systemic trial comparing neoadjuvant chemotherapy with neoadjuvant endocrine therapy in pre-menopausal patients with estrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Front Oncol. 2021;11:741120. doi: 10.3389/fonc.2021.741120 PMID: 34660302; PMCID: PMC8515848.
   PubMedGoogle Scholar
• Cardoso F, van’t Veer LJ, Bogaerts J, et al. MINDACT investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–729. doi: 10.1056/NEJMoa1602253 PMID: 27557300.
   PubMed Web of Science ®Google Scholar
• Griguolo G, Bottosso M, Vernaci G, et al. Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: available evidence and clinical implications. Cancer Treat Rev. 2022;102:102323. doi: 10.1016/j.ctrv.2021.102323 PMID: 34896969.
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Kelly C, Mizoo T, et al. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Clin Breast Cancer. 2016;16(2):95–100.e1. doi: 10.1016/j.clbc.2015.10.004 PMID: 26631838
   PubMed Web of Science ®Google Scholar
• Pease AM, Riba LA, Gruner RA, et al. Oncotype DX® recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26(2):366–371. doi: 10.1245/s10434-018-07107-8 PMID: 30542840.
   PubMed Web of Science ®Google Scholar
• Kantor O, Barrera E, Kopkash K, et al. Are we overtreating hormone receptor positive breast cancer with neoadjuvant chemotherapy? Role of OncotypeDx® for hormone receptor positive patients undergoing neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26(10):3232–3239. doi: 10.1245/s10434-019-07555-w PMID: 31342379.
   PubMed Web of Science ®Google Scholar
• Morales Murillo S, Gasol Cudos A, Veas Rodriguez J, et al. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer. Breast. 2021;56:35–41. doi: 10.1016/j.breast.2021.01.001 PMID: 33601299; PMCID: PMC7900764.
   PubMed Web of Science ®Google Scholar
• Taylor C, Meisel J, Foreman AJ, et al. Using oncotype DX breast recurrence score assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2023;199(1):91–98. doi: 10.1007/s10549-023-06890-7 PMID: 36897465; PMCID: PMC10147793
   PubMed Web of Science ®Google Scholar
• Krijgsman O, Roepman P, Zwart W, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012;133(1):37–47. doi: 10.1007/s10549-011-1683-z PMID: 21814749.
   PubMed Web of Science ®Google Scholar
• Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010;119(3):551–558. doi: 10.1007/s10549-009-0333-1 PMID: 19214742.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Viens P, et al. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer Lett. 2014;355(1):70–75. doi: 10.1016/j.canlet.2014.09.014 PMID: 25218596
   PubMed Web of Science ®Google Scholar
• Farrugia DJ, Landmann A, Zhu L, et al. Magee equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol. 2017;30(8):1078–1085. doi: 10.1038/modpathol.2017.41 PMID: 28548119
   PubMed Web of Science ®Google Scholar
• Bhargava R, Esposito NN, Oʹconnor SM, et al. Magee equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study. Mod Pathol. 2021;34(1):77–84. doi: 10.1038/s41379-020-0620-2 PMID: 32661297
   PubMed Web of Science ®Google Scholar
• Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149–160. doi: 10.1016/S1470-2045(21)00589-1 PMID: 34902335; PMCID: PMC9455620
   PubMed Web of Science ®Google Scholar
• Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–4422. doi: 10.1200/JCO.2007.10.6823 PMID: 17785706
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi: 10.1016/S0140-6736(13)62422-8 PMID: 24529560.
   PubMed Web of Science ®Google Scholar
• Villegas SL, Nekljudova V, Pfarr N, et al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - an analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer. 2021;148:159–170. doi: 10.1016/j.ejca.2021.02.020 PMID: 33743484.
   PubMed Web of Science ®Google Scholar
• Davey MG, Ryan ÉJ, Folan PJ, et al. The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer. BJS Open. 2021;5(3):zrab040. doi: 10.1093/bjsopen/zrab040 PMID: 34013318; PMCID: PMC8134515.
   PubMed Web of Science ®Google Scholar
• Lee EG, Lee DE, Kim HH, et al. Androgen receptor as a predictive Marker for pathologic complete response in hormone receptor–positive and HER-2–negative breast cancer with neoadjuvant chemotherapy. Cancer Res Treat. 2022 Sep 8;55(2): 542–550. doi: 10.4143/crt.2022.834 Epub ahead of print. PMID: 36097802.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113(7):808–819. doi: 10.1093/jnci/djaa201 PMID: 33369635; PMCID: PMC8487652
   PubMedGoogle Scholar
• Ellis MJ, Suman VJ, Hoog J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons oncology group Z1031 trial (alliance). J Clin Oncol. 2017;35(10):1061–1069. doi: 10.1200/JCO.2016.69.4406 PMID: 28045625; PMCID: PMC5455353
   PubMed Web of Science ®Google Scholar
• Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273–4278. doi: 10.1200/JCO.2010.31.2835 PMID: 21990413
   PubMed Web of Science ®Google Scholar
• Elsamany S, Elmorsy S, Alzahrani A, et al. Predictive value of IHC4 score for pathological response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. Asian Pac J Cancer Prev. 2015;16(17):7975–7979. doi: 10.7314/apjcp.2015.16.17.7975 PMID: 26625828
   PubMedGoogle Scholar
• Tan W, Luo W, Jia W, et al. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer. Oncotarget. 2016;7(52):87312–87322. doi: 10.18632/oncotarget.13549 PMID: 27894097; PMCID: PMC5349990.
   PubMedGoogle Scholar
• Sheri A, Smith IE, Johnston SR, et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol. 2015 Jan;26(1):75–80. doi: 10.1093/annonc/mdu508 PMID: 25361988.
   PubMed Web of Science ®Google Scholar
• Rosso C, Voutsadakis IA. Characteristics, clinical differences and outcomes of breast cancer patients with negative or low HER2 expression. Clin Breast Cancer. 2022;22(4):391–397. doi: 10.1016/j.clbc.2022.02.008 PMID: 35337735.
   PubMed Web of Science ®Google Scholar
• Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151–1161. doi: 10.1016/S1470-2045(21)00301-6 PMID: 34252375
   PubMed Web of Science ®Google Scholar
• O’Donnell JPM, Gasior SA, Davey MG, et al. The accuracy of breast MRI radiomic methodologies in predicting pathological complete response to neoadjuvant chemotherapy: a systematic review and network meta-analysis. Eur J Radiol. 2022;157:110561. doi: 10.1016/j.ejrad.2022.110561 PMID: 36308849.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi: 10.1093/annonc/mdz173 PMID: 31161190
   PubMed Web of Science ®Google Scholar
• Leal F, Liutti VT, Antunes dos Santos VC, et al. Neoadjuvant endocrine therapy for resectable breast cancer: a systematic review and meta-analysis. Breast. 2015;24(4):406–412. doi: 10.1016/j.breast.2015.03.004 PMID: 25858103
   PubMed Web of Science ®Google Scholar
• Mustacchi G, Ceccherini R, Milani S, et al., Italian Cooperative Group GRETA. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol. 2003;14(3):414–420. doi: 10.1093/annonc/mdg117 PMID: 12598347.
   PubMed Web of Science ®Google Scholar
• Gazet JC, Ford HT, Coombes RC, et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol. 1994;20(3):207–214. PMID: 8181594
   PubMedGoogle Scholar
• Eiermann W, Paepke S, Appfelstaedt J, et al., Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–1532. doi: 10.1023/a:1013128213451 PMID: 11822750.
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR, et al., IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–5116. doi: 10.1200/JCO.2005.04.005 PMID: 15998903.
   PubMed Web of Science ®Google Scholar
• Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “arimidex” compared to tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–2103. doi: 10.1002/cncr.21872 PMID: 16598749.
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–2349. doi: 10.1200/JCO.2010.31.6950 PMID: 21555689; PMCID: PMC3107749
   PubMed Web of Science ®Google Scholar
• Barnadas A, Gil M, González S, et al. Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer. 2009;100(3):442–449. doi: 10.1038/sj.bjc.6604868 PMID: 19156139; PMCID: PMC2658534.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Dixon JM, Sibbering DM, et al. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. Breast Cancer Res. 2013;15(2):R18. doi: 10.1186/bcr3393 PMID: 23497452; PMCID: PMC3672778.
   PubMed Web of Science ®Google Scholar
• AlSaleh K, Al Zahwahry H, Bounedjar A, et al. Response to induction neoadjuvant hormonal therapy using upfront 21-gene breast recurrence score assay—results from the SAFIA phase III trial. JCO Glob Oncol. 2021;7(7):811–819. doi: 10.1200/GO.20.00575 PMID: 34086481; PMCID: PMC8457874
   PubMedGoogle Scholar
• Garcia-Fructuoso I, Gomez-Bravo R, Schettini F. Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment. Curr Opin Oncol. 2022;34(6):635–642. doi: 10.1097/CCO.0000000000000892 PMID: 36000362.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Noh WC, Lee ES, et al. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Res. 2020;22(1):54. doi: 10.1186/s13058-020-01288-5 PMID: 32460816; PMCID: PMC7251809.
   PubMed Web of Science ®Google Scholar
• Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13(4):345–352. doi: 10.1016/S1470-2045(11)70373-4 PMID: 22265697
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A, Guerrero Á, Galán A, et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol. 2012;14(2):125–131. doi: 10.1007/s12094-012-0771-9 PMID: 22301401.
   PubMed Web of Science ®Google Scholar
• Charehbili A, Fontein DB, Kroep JR, et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat Rev. 2014;40(1):86–92. doi: 10.1016/j.ctrv.2013.06.001 PMID: 23891267
   PubMed Web of Science ®Google Scholar
• Thibodeau S, Voutsadakis IA. The oncotype dx assay in ER-Positive, HER2-negative breast cancer patients: a real life experience from a single cancer center. Eur J Breast Health. 2019;15(3):163–170. doi: 10.5152/ejbh.2019.4901 PMID: 31312792; PMCID: PMC6619784.
   PubMed Web of Science ®Google Scholar
• Iwata H, Masuda N, Yamamoto Y, et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat. 2019;173(1):123–133. doi: 10.1007/s10549-018-4964-y PMID: 30242578; PMCID: PMC6394785.
   PubMed Web of Science ®Google Scholar
• Akashi-Tanaka S, Shimizu C, Ando M, et al. 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast. 2009;18(3):171–174. doi: 10.1016/j.breast.2009.03.005 PMID: 19410462
   PubMed Web of Science ®Google Scholar
• Ueno T, Masuda N, Yamanaka T, et al. Evaluating the 21-gene assay recurrence score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. Int J Clin Oncol. 2014;19(4):607–613. doi: 10.1007/s10147-013-0614-x PMID: 24101215.
   PubMed Web of Science ®Google Scholar
• Inda MA, Blok EJ, Kuppen PJK, et al. Estrogen receptor pathway activity score to predict clinical response or resistance to neoadjuvant endocrine therapy in primary breast cancer. Mol Cancer Ther. 2020;19(2):680–689. doi: 10.1158/1535-7163.MCT-19-0318 PMID: 31727690
   PubMed Web of Science ®Google Scholar
• Du L, Yau C, Brown-Swigart L, et al. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Ann Oncol. 2021;32(5):642–651. doi: 10.1016/j.annonc.2021.02.011 PMID: 33617937
   PubMed Web of Science ®Google Scholar
• Suman VJ, Du L, Hoskin T, et al. Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (alliance Z1031). Clin Cancer Res. 2022;28(15):3287–3295. doi: 10.1158/1078-0432.CCR-22-0068 PMID: 35653124; PMCID: PMC9357183
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380–1388. doi: 10.1093/jnci/djn309 PMID: 18812550; PMCID: PMC2556704
   PubMedGoogle Scholar
• Suman VJ, Ellis MJ, Ma CX. The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer. Chin Clin Oncol. 2015;4(3):34. doi: 10.3978/j.issn.2304-3865.2015.09.01 PMID: 26408301; PMCID: PMC4734643.
   PubMed Web of Science ®Google Scholar
• Ma CX, Suman VJ, Leitch AM. ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. J Clin Oncol. 2020;38(15 suppl):504–504.
   Web of Science ®Google Scholar
• Dowsett M, Smith IE, Ebbs SR, et al., IMPACT Trialists Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99(2):167–170. doi: 10.1093/jnci/djk020 PMID: 17228000.
   PubMed Web of Science ®Google Scholar
• Smith I, Robertson J, Kilburn L, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020;21(11):1443–1454. doi: 10.1016/S1470-2045(20)30458-7 PMID: 33152284; PMCID: PMC7606901
   PubMed Web of Science ®Google Scholar
• Doostan I, Karakas C, Kohansal M, et al. Cytoplasmic cyclin E mediates resistance to aromatase inhibitors in breast cancer. Clin Cancer Res. 2017;23(23):7288–7300. doi: 10.1158/1078-0432.CCR-17-1544 PMID: 28947566; PMCID: PMC5768442
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Fasching PA, Hurvitz S, et al. Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023;15:17588359231178125. doi: 10.1177/17588359231178125 PMID: 37275963; PMCID: PMC10233570.
   Web of Science ®Google Scholar
• Johnston SRD, Toi M, O’Shaughnessy J, et al. monarchE committee members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77–90. doi: 10.1016/S1470-2045(22)00694-5 PMID: 36493792
   PubMed Web of Science ®Google Scholar
• Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22(2):212–222. doi: 10.1016/S1470-2045(20)30642-2 PMID: 33460574
   PubMed Web of Science ®Google Scholar
• Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-Positive and HER2-negative early breast cancer-the penelope-B trial. J Clin Oncol. 2021;39(14):1518–1530. doi: 10.1200/JCO.20.03639 PMID: 33793299
   PubMed Web of Science ®Google Scholar
• Johnston S, Puhalla S, Wheatley D, et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol. 2019;37(3):178–189. doi: 10.1200/JCO.18.01624 PMID: 30523750.
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Martin M, Press MF, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+/HER2− breast cancer. Clin Cancer Res. 2020;26(3):566–580. doi: 10.1158/1078-0432.CCR-19-1425 PMID: 31615937; PMCID: PMC7498177
   PubMed Web of Science ®Google Scholar
• Khan QJ, O’Dea A, Bardia A, et al. Letrozole+ribociclib versus letrozole+placebo as neoadjuvant therapy for ER+breast cancer (FELINE trial). J Clin Oncol. 2020 May 20;38(15_suppl):505–505. doi: 10.1200/JCO.2020.38.15_suppl.505
   Web of Science ®Google Scholar
• Ma CX, Gao F, Luo J, et al. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2017;23(15):4055–4065. doi: 10.1158/1078-0432.CCR-16-3206 PMID: 28270497; PMCID: PMC5555232
   PubMed Web of Science ®Google Scholar
• Chow LWC, Morita S, Chow CYC, et al. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value. Endocr Relat Cancer. 2018;25(2):123–130. doi: 10.1530/ERC-17-0396 PMID: 29158285; PMCID: PMC5763422.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Kilburn L, Rimawi MF, et al. Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2− breast cancer. Clin Cancer Res. 2022;28(1):163–174. doi: 10.1158/1078-0432.CCR-21-1628 PMID: 34645649; PMCID: PMC9632606.
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Bardia A, Quiroga V, et al., coopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA breast cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023;24(9):1029–1041. doi: 10.1016/S1470-2045(23)00268-1 PMID: 37657462.
   PubMed Web of Science ®Google Scholar
• Cottu P, D’Hondt V, Dureau S, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018 Dec 1;29(12):2334–2340. doi:10.1093/annonc/mdy448 PMID: 30307466
   PubMed Web of Science ®Google Scholar
• Delaloye S, Dureau S, D’Hondt V, et al. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. Eur J Cancer. 2022;166:300–308. doi: 10.1016/j.ejca.2022.01.014
   PubMed Web of Science ®Google Scholar
• Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33–43. doi: 10.1016/S1470-2045(19)30786-7 PMID: 31838010
   PubMed Web of Science ®Google Scholar
• Curigliano G, Gomez Pardo P, Meric-Bernstam F, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast. 2016;28:191–8. doi: 10.1016/j.breast.2016.06.008 PMID: 27336726.
   PubMed Web of Science ®Google Scholar
• Arnedos M, Bayar MA, Cheaib B, et al. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Ann Oncol. 2018;29(8):1755–1762. doi: 10.1093/annonc/mdy202 PMID: 29893769
   PubMed Web of Science ®Google Scholar
• Yue W, Fan P, Wang J, et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol. 2007;106(1–5):102–110. doi: 10.1016/j.jsbmb.2007.05.008 PMID: 17616457.
   PubMed Web of Science ®Google Scholar
• Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer. J Clin Invest. 2010;120(7):2406–2413. doi: 10.1172/JCI41680 PMID: 20530877
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2012;366(6):520–529. doi: 10.1056/NEJMoa1109653 PMID: 22149876
   PubMed Web of Science ®Google Scholar
• Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO-2 final progression free survival analysis. Adv Ther. 2013;30(10):870–884. doi: 10.1007/s12325-013-0060-1 PMID: 24158787
   PubMed Web of Science ®Google Scholar
• Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357–2362. doi: 10.1093/annonc/mdu456 PMID: 25231953
   PubMed Web of Science ®Google Scholar
• Bachelot T, Cottu P, Chabaud S, et al. Everolimus added to adjuvant endocrine therapy in patients with high-risk hormone receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer. J Clin Oncol. 2022;40(32):3699–3708. doi: 10.1200/JCO.21.02179 PMID: 35605174
   PubMed Web of Science ®Google Scholar
• Guarneri V, Giorgi CA, Cinieri S, et al. Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: final results of the phase III randomized MAIN-A (MAINtenance afinitor) trial. Cancer. 2021;154:21–29. doi: 10.1016/j.ejca.2021.05.008 PMID: 34225066.
   Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor positive breast cancer. J Clin Oncol. 2009;27(16):2630–2637. doi: 10.1200/JCO.2008.18.8391 PMID: 19380449
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484. doi: 10.1016/j.cell.2006.01.016 PMID: 16469695.
   PubMed Web of Science ®Google Scholar
• Kim EK, Kim JH, Kim HA, et al. Phosphorylated S6 kinase-1: a breast cancer marker predicting resistance to neoadjuvant chemotherapy. Anticancer Res. 2013;33(9):4073–9. PMID: 24023352
   PubMed Web of Science ®Google Scholar
• Voss MH, Gordon MS, Mita M, et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020;123(11):1590–1598. doi: 10.1038/s41416-020-01041-x PMID: 32913286; PMCID: PMC7686313.
   PubMed Web of Science ®Google Scholar
• Koca E, Niravath PA, Ensor J, et al. ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2021;188(2):433–439. doi: 10.1007/s10549-021-06214-7 PMID: 33860388
   PubMed Web of Science ®Google Scholar
• Keegan NM, Gleeson JP, Hennessy BT, et al. PI3K inhibition to overcome endocrine resistance in breast cancer. Expert Opin Investig Drugs. 2018;27(1):1–15. doi: 10.1080/13543784.2018.1417384 PMID: 29252036.
   PubMed Web of Science ®Google Scholar
• Saura C, Hlauschek D, Oliveira M, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019;20(9):1226–1238. doi: 10.1016/S1470-2045(19)30334-1 PMID: 31402321
   PubMed Web of Science ®Google Scholar
• Cerma K, Piacentini F, Moscetti L, et al. Targeting PI3K/AKT/mTOR pathway in breast cancer: from biology to clinical challenges. Biomedicines. 2023;11(1):109. doi: 10.3390/biomedicines11010109 PMID: 36672617; PMCID: PMC9855880.
   PubMed Web of Science ®Google Scholar
• Howell SJ, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022;23(7):851–864. doi: 10.1016/S1470-2045(22)00284-4 PMID: 35671774.
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Coleman RE, Cheung KL, et al. Proliferation and AKT activity biomarker analyses after capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clin Cancer Res. 2020;26(7):1574–1585. doi: 10.1158/1078-0432.CCR-19-3053
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208–217. doi: 10.1016/j.annonc.2020.11.011 PMID: 33246021
   PubMed Web of Science ®Google Scholar
• Turner NC, Oliveira M, Howell SJ, et al., CAPItello-291 Study Group. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058–2070. doi: 10.1056/NEJMoa2214131 PMID: 37256976.
   PubMed Web of Science ®Google Scholar
• Behl S, Hamel N, de Ladurantaye M, et al. Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls. Sci Rep. 2020;10(1):6491. doi: 10.1038/s41598-020-63100-w PMID: 32300229
   PubMed Web of Science ®Google Scholar
• Hu C, Polley EC, Yadav S, et al. The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer from a Clinical Genetic Testing Cohort. J Natl Cancer Inst. 2020;112(12):1231–1241. doi: 10.1093/jnci/djaa023 PMID: 32091585
   PubMedGoogle Scholar
• Rinaldi J, Sokol ES, Hartmaier RJ, et al. The genomic landscape of metastatic breast cancer: insights from 11,000 tumors. PLoS One. 2020;15(5):e0231999. doi: 10.1371/journal.pone.0231999 PMID: 32374727
   PubMed Web of Science ®Google Scholar
• CE G Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250–1268. doi: 10.1016/j.annonc.2022.09.159 PMID: 36228963.
   PubMed Web of Science ®Google Scholar
• Fasching PA, Link T, Hauke J, et al., German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2021;32(1):49–57. doi: 10.1016/j.annonc.2020.10.471 PMID: 33098995.
   PubMed Web of Science ®Google Scholar
• Litton JK, Scoggins M, Hess KR, et al. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA pathogenic variant. J Clin Oncol. 2020;38(5):388–394. doi: 10.1200/JCO.19.01304 PMID: 31461380
   PubMed Web of Science ®Google Scholar
• Litton JK, Scoggins M, Ramirez DL, et al. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 2017;3:49. doi: 10.1038/s41523-017-0052-4 PMID: 29238749; PMCID: PMC5719044.
   PubMed Web of Science ®Google Scholar
• Spring LM, Han H, Liu MC, et al. Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat Cancer. 2022;3(8):927–931. doi: 10.1038/s43018-022-00400-2 PMID: 35788722; PMCID: PMC9402431.
   PubMedGoogle Scholar
• Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–117. doi: 10.1016/S0140-6736(22)02420-5 PMID: 36495879
   PubMed Web of Science ®Google Scholar
• Nicolò E, Zagami P, Curigliano G. Antibody-drug conjugates in breast cancer: the chemotherapy of the future? Curr Opin Oncol. 2020;32(5):494–502. doi: 10.1097/CCO.0000000000000656 PMID: 32657795.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105–2122. doi: 10.1200/JCO.2018.77.8738 PMID: 29846122
   PubMed Web of Science ®Google Scholar
• Cortés J, Kim SB, Chung WP, et al. DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143–1154. doi: 10.1056/NEJMoa2115022 PMID: 35320644.
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, DESTINY-Breast04 Trial Investigators, et al. Trastuzumab deruxtecan in Previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi: 10.1056/NEJMoa2203690 PMID: 35665782.
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz S, Press MF, et al. GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer [abstract]. Cancer Res. 2023;83(5 Suppl):Abstract nr GS2–03.
   Web of Science ®Google Scholar
• Rugo HS, Bianchini G, Cortes J, et al. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7(4):100553. doi: 10.1016/j.esmoop.2022.100553 PMID: 35964548; PMCID: PMC9375150
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546. doi: 10.1056/NEJMoa1910836 PMID: 31562797.
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF, Longo DL. Precision diagnosis and treatment for advanced non–small-Cell lung cancer. N Engl J Med. 2017;377(9):849–861. doi: 10.1056/NEJMra1703413 PMID: 28854088.
   PubMed Web of Science ®Google Scholar
• Jacob SL, Huppert LA, Rugo HS. Role of immunotherapy in breast cancer. JCO Oncology Practice. 2023 Jan 6;19(4):167–179. doi: 10.1200/OP2200483 Epub ahead of print. PMID: 36608303.
   PubMedGoogle Scholar
• Voutsadakis IA. Immune blockade inhibition in breast cancer. Anticancer Res. 2016;36(11):5607–5622. doi: 10.21873/anticanres.11145 PMID: 27793883.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, KEYNOTE-522 Investigators, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–567. doi: 10.1056/NEJMoa2112651 PMID: 35139274.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. High tumor mutation burden and other immunotherapy response predictors in breast cancers: associations and therapeutic opportunities. Target Oncol. 2020;15(1):127–138. doi: 10.1007/s11523-019-00689-7 PMID: 31741177.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. The landscape of chromosome instability in breast cancers and associations with the tumor mutation burden: an analysis of data from TCGA. Cancer Invest. 2021;39(1):25–38. doi: 10.1080/07357907.2020.1863418 PMID: 33306412.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. High mutation burden in ER-Positive/HER2-negative/Luminal breast cancers. J Clin Med. 2022;11(6):1605. doi: 10.3390/jcm11061605 PMID: 35329928; PMCID: PMC8953761.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Delord JP, Im SA, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/Human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res. 2018;24(12):2804–2811. doi: 10.1158/1078-0432.CCR-17-3452 PMID: 29559561
   PubMed Web of Science ®Google Scholar
• Loi S, Curigliano G, Salgado RF, et al. LBA20 a randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC). Ann Oncol. 2023;34:S1259–S1260.
   Google Scholar
• Cardoso F, McArthur HL, Schmid P, et al. LBA21 KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. Annals Of Oncology. 2023;34:S1260–S1261. doi: 10.1016/j.annonc.2023.10.011
   Google Scholar
• Gandhi S, Brackstone M, Hong NJL, et al. Canadian national neoadjuvant breast cancer consortium. A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. Breast Cancer Res Treat. 2022;193(1):1–20. doi: 10.1007/s10549-022-06522-6 PMID: 35224713; PMCID: PMC8993711.
   PubMed Web of Science ®Google Scholar
• Stravodimou A, Voutsadakis IA. The future of ER+/HER2- metastatic breast cancer therapy: beyond PI3K inhibitors. Anticancer Res. 2020;40(9):4829–4841. doi: 10.21873/anticanres.14486 PMID: 32878771.
   PubMed Web of Science ®Google Scholar
• Pagliuca M, Donato M, D’Amato AL, et al. New steps on an old path: novel estrogen receptor inhibitors in breast cancer. Crit Rev Oncol Hematol. 2022;180:103861. doi: 10.1016/j.critrevonc.2022.103861 PMID: 36374739.
   PubMed Web of Science ®Google Scholar
• Lin X, Xiang H, Luo G. Targeting estrogen receptor α for degradation with PROTACs: a promising approach to overcome endocrine resistance. Eur J Med Chem. 2020;206:112689. doi: 10.1016/j.ejmech.2020.112689 PMID: 32829249.
   PubMed Web of Science ®Google Scholar
• [cited 2023 Dec 15]. Available from: www.clinicaltrials.gov
   Google Scholar